Biogen vet Adam Koppel is raising cash for a new life sciences fund at Bain Capital
Following a two-year stint as chief strategy officer for Biogen, Adam Koppel took a new job last June helming Bain Capital’s investments in biotech and life sciences. And now he’s gathering the cash for a new fund.
Koppel’s listed in the Form D filed with the SEC for Bain Capital Life Sciences today, where he’s taken the role of managing director. And while it doesn’t list an amount, Bain has a long history of making a splash in whatever field it’s working in, with more than $75 billion in managed capital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.